Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103336 | 0.79 | CDK4 (0.39) | CDK4CCND1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1102610 | 0.77 | MAPK10 (0.33) | — | |
| SCHEMBL1103027 | 0.77 | ALDH1A1 (0.31) | — | |
| SCHEMBL1103479 | 0.77 | ESR1 (0.42) | CDK4CCND1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1103449 | 0.77 | ESR1 (0.42) | CDK4CCND1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1103486 | 0.77 | ESR1 (0.42) | CDK4CCND1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1103491 | 0.77 | ESR1 (0.42) | CDK4CCND1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1103358 | 0.76 | MAP4K4 (0.39) | CDK4CCND1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1103483 | 0.76 | ESR1 (0.42) | CDK4CCND1PDPK1 | |
| SCHEMBL1103478 | 0.76 | ESR1 (0.42) | CDK4CCND1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | CDK4 1577/4885CCND1 22/4885PIK3CD 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.